BioNTech (NASDAQ:BNTX) Trading Up 0.5% – Here’s Why

Shares of BioNTech SE (NASDAQ:BNTX) traded up 0.5% on Monday . The stock traded as high as $119.65 and last traded at $119.02. 89,837 shares were traded during mid-day trading, a decline of 89% from the average session volume of 812,618 shares. The stock had previously closed at $118.39.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on BNTX. HC Wainwright reissued a “buy” rating and issued a $150.00 target price on shares of BioNTech in a report on Monday, November 18th. UBS Group lifted their price objective on BioNTech from $97.00 to $131.00 and gave the company a “neutral” rating in a report on Wednesday, September 18th. Bank of America boosted their target price on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Berenberg Bank started coverage on shares of BioNTech in a research report on Tuesday, November 19th. They set a “buy” rating and a $130.00 target price for the company. Finally, BMO Capital Markets restated an “outperform” rating on shares of BioNTech in a research report on Monday. Four investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $138.67.

BioNTech Stock Down 0.3 %

The firm has a 50 day moving average price of $113.83 and a 200-day moving average price of $99.12. The firm has a market cap of $27.62 billion, a price-to-earnings ratio of -55.04 and a beta of 0.22. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX) last issued its earnings results on Monday, November 4th. The company reported $0.81 earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. During the same quarter last year, the firm earned $0.73 EPS. The company’s revenue for the quarter was up 38.9% on a year-over-year basis. As a group, equities analysts predict that BioNTech SE will post -3.72 EPS for the current fiscal year.

Institutional Trading of BioNTech

A number of institutional investors have recently bought and sold shares of BNTX. FMR LLC boosted its position in shares of BioNTech by 797.8% in the 3rd quarter. FMR LLC now owns 6,299,929 shares of the company’s stock worth $748,243,000 after purchasing an additional 5,598,190 shares during the last quarter. Fred Alger Management LLC acquired a new position in shares of BioNTech during the 3rd quarter worth about $59,485,000. Candriam S.C.A. grew its position in shares of BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after buying an additional 418,695 shares during the period. Point72 Asset Management L.P. increased its stake in shares of BioNTech by 283.5% in the 2nd quarter. Point72 Asset Management L.P. now owns 461,711 shares of the company’s stock valued at $37,103,000 after acquiring an additional 341,311 shares during the last quarter. Finally, Braidwell LP acquired a new stake in shares of BioNTech in the 3rd quarter valued at approximately $29,425,000. Institutional investors and hedge funds own 15.52% of the company’s stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.